Abstract
OBJECTIVE: To perform an outcome analysis of patients with low-risk gestational trophoblastic neoplasia (GTN) treated with a 5-day intramuscular methotrexate (MTX) regimen on a 21-day cycle. STUDY DESIGN: A retrospective review of 31 patients with low-risk GTN treated with a 5-day MTX regimen. RESULTS: A total of 31 patients with low-risk GTN (WHO score < 7) received single-agent MTX at a dose of 0.4 mg/kg daily for 5 days every 21 days (mean number of cycles, 3; 83% remission). The only significant toxicity encountered was grade 2 stomatitis in 8 (26%) patients. CONCLUSION: A 5-day MTX regimen given every 21 days is convenient, well-tolerated and effective for patients with low-risk GTN.
| Original language | English |
|---|---|
| Pages (from-to) | 411-414 |
| Number of pages | 4 |
| Journal | Journal of Reproductive Medicine |
| Volume | 57 |
| Issue number | 9-10 |
| State | Published - Oct 2012 |
Keywords
- Chemotherapy
- Gestational trophoblastic neoplasia
- Methotrexate
Fingerprint
Dive into the research topics of 'Methotrexate on a 21-day cycle for low-risk gestational trophoblastic neoplasia'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver